


At A CAGR of 13.5% CAR T-Cell therapy Market Is Projected to Reach \$6.1 Billion by 2031

Chimeric antigen receptor (CAR) T cell therapy treats certain cancers by converting T cells into cells that are more effective in fighting cancer.

PORTLAND, OREGON, UNITED STATES, October 14, 2022 /EINPresswire.com/ -- Allied Market Research published a report, titled, "CAR T-Cell Therapy Market by Drug type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), by



Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), by End user (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global CAR T-cell therapy industry generated \$1.7 billion in 2021, and is expected to reach \$6.1 billion by 2031, witnessing a CAGR of 13.5% from 2022 to 2031.

Chimeric antigen receptor (CAR) T cell therapy treats certain cancers by converting T cells into cells that are more effective in fighting cancer. CAR T-cell therapy is a new targeted approach, which involves the genetic engineering of T cells to target specific receptors on cancer cells.

https://www.alliedmarketresearch.com/request-sample/17358

Major Key market players covered in the report -

Autolus Therapeutics, Bluebird bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cartesian Therapeutics, Inc., Celgene Corporation, Cellectis, Celyad Oncology, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc., Sorrento Therapeutics, Inc.

Key Benefits for Stakeholders -

• This report provides a quantitative analysis of market segments, current trends, strategies and

capabilities of Car T Cell Therapy market research from 2021 to 2031 to identify the market opportunities of T cell therapy for cars.

- In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
- Market analysis and information related to key drivers, restraints and opportunities are provided. Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- The report includes regional and global car t-cell therapy market analysis, key players, market segments, application areas and Market growth strategies.

North America is expected to experience the strongest revenue growth, driven by rising cancer rates, strong healthcare infrastructure, the presence of major players, and increased healthcare spending. However, Asia-Pacific is expected to experience significant growth, due to increasing geriatric population, unmet healthcare needs, government and non-governmental organizations (NGO) initiatives to raise awareness about CAR T-cell therapy and increase in the public. investment in the health sector.

TABLE OF CONTENT -

CHAPTER 1 - INTRODUCTION:

- 1.1. Report description
- 1.2. Key market segments
- 1.3. List of key players profiled in the report
- 1.4. Research methodology
- 1.4.1. Secondary research
- 1.4.2. Primary research
- 1.4.3. Analyst tools & models

CHAPTER 2 - EXECUTIVE SUMMARY:

- 2.1. Key findings of the study
- 2.2. CXO Perspective

Market: By Region Outlook

- North America (U.S., Canada, Mexico)
- Europe (UK, Germany, France, Spain, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
- LAMEA (Brazil, South Africa, Turkey, Saudi Arabia, Rest of LAMEA)

By drug type, the axicabtagen ciloleucel segment is the largest contributor to market revenue due to increased approval of axicabtagen ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma in relapsed and it is refractory follicular lymphoma. The autoleucel brexucabattagen segment is expected to witness the highest CAGR during the forecast period, due to the increase in the approval of CAR T-cell therapy in various countries for acute lymphoblastic leukemia (ALL) in relapses and it is refractory B cell precursors.

0 000 000 0000 000000, 00000 0000:

https://www.alliedmarketresearch.com/checkout-final/02914d65babbbc26355a40a80fc79c79

On the basis of the end user, the hospital sector is the largest contributor to the market revenue in 2021, due to factors such as more efficient rooms, higher purchasing power and increased patient acceptance. The cancer treatment segment is expected to experience the highest CAGR during the forecast period, due to the availability of various treatment options and the increase in the number of cancer sites in some developing countries.

Frequently Asked Questions?

- Q1. What is the total market value of car t-cell therapy market report?
- Q2. Which are the top companies holding the market share in car t-cell therapy market?
- Q3. Which are the largest regions for this Market?
- Q4. What is the leading technology of car t-cell therapy market?
- Q5. What are the major drivers for this specific Market?
- Q6. What are the upcoming key trends in the car t-cell therapy market report?

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with vario research data tables and confirms utmost accuracy in our market forecasting. Each and ever us companies and this helps us in digging out market data that helps us generate accurate y data

presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 503-894-6022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/595789464

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.